Longevity III: Drugs, Supplements, and Interventions

Pills, Potions, and Sorcery - Longevity Drugs, Supplements and Interventions

The single most common question I get in the longevity space is some version of: is there a chemical that will actually make me live longer? People want the holy grail — a pill, a peptide, a protocol — that requires minimal effort and delivers more years on the clock. I understand the appeal. I also have to tell you the truth.

The Core Problem: We Don't Have the Data

Before we can talk about specific drugs, we have to acknowledge what we don't know. There is no medication, supplement, or substance that has been studied over the course of an actual human lifespan for its effect on longevity. The reason is mundane: those trials would cost hundreds of millions of dollars and take the better part of a century. Nobody's writing that check.

So science does what science does. It uses surrogate markers — and the closest thing we have to a real answer is the Interventions Testing Program (ITP), which takes applications for substances and tests whether they extend lifespan in mice. Not a perfect proxy for humans, but it's the best proxy we have.

The list of interventions that have actually passed this test is short. Rapamycin. 17-alpha estradiol (in male mice). Acarbose. Empagliflozin. Enalapril. That's most of it.

Plenty of drugs haven't been tested yet. GLP-1 agonists almost certainly belong on this list eventually — I'd bet money on it. But here's the other thing to keep in mind: I'm skeptical that stacking multiple lifespan-extending drugs produces synergistic benefit. More is not always more.

One more note on the ITP. It evaluates both pharmaceuticals and nutraceuticals. To date, not a single nutraceutical has extended lifespan in this trial. That should matter to how you think about your supplement cabinet.

Primary Prevention vs. Secondary Prevention

Before the conversation can go anywhere useful, you have to ask a second question: does this person already have a disease, or are we trying to prevent one from showing up?

This is the difference between primary and secondary prevention, and it changes everything. Primary prevention is giving someone a medication before they have an underlying disease state. The data here is, broadly, not great. Secondary prevention — treating someone who already has an identified problem — is where the evidence gets much stronger. Once a patient has a known disease and we intervene, we can meaningfully extend lifespan. That's real.

The caveat: secondary prevention doesn't eliminate the underlying disease. It manages it. And my belief, from years of doing this, is that most chronic conditions can be substantially mitigated by improving someone's underlying state of health. Not all. But most. The disease doesn't have to be the end of the story.

Pills, Potions, and Sorcery

This is where the term I use comes from. Outside of a few proven interventions, what gets sold to the public is largely pills, potions, and sorcery — the newest gadget, the newest peptide, the newest panel of labs that's going to unlock your biological age. We're drawn to novelty because novelty feels like hope.

Science and technology are not currently in a position to radically increase longevity for the general population. We've made extraordinary advances in narrow cases — certain cancers, certain genetic conditions, critical care — where we've added real years to real lives. Those are the exceptions, not the rule.

The Big Four: Where We Actually Have Tools

The major killers in the United States remain cardiovascular disease, cancer, neurodegenerative disease, and metabolic syndrome. The honest report card on each looks like this:

Metabolic syndrome. This is where we've made the most progress in the last decade, full stop. GLP-1 agonists are a genuine breakthrough. SGLT-2 inhibitors are another class with real cardiovascular and kidney benefit — and as the patents expire and generics come online, the cost barrier that has kept them out of reach is finally starting to fall. Metformin is still up for debate. Acarbose works on paper but most people can't tolerate it — the GI side effects drive most patients off the drug within weeks.

Cardiovascular disease. Blood pressure control with ACE inhibitors and ARBs likely reduces mortality. There's reasonable data for calcium channel blockers as well. Magnesium is a nutraceutical worth mentioning — modest effect, but a real one. And anything that increases nitric oxide — the phosphodiesterase inhibitors like sildenafil and tadalafil (Viagra and Cialis) — may have benefits beyond what they're marketed for.

Then there's the great debate: lipid-lowering agents. Statins are where people get emotional. Some clinicians will tell you there's no debate at all — if you lower LDL, you reduce cardiovascular mortality, end of discussion. The new guidelines that came out in March of 2026 are considerably more aggressive than previous recommendations, both for lipids and for blood pressure targets. PCSK9 inhibitors can lower LDL dramatically and are likely beneficial, but they remain cost-prohibitive for most patients. Whether you can meaningfully extend life by optimizing every biometric — blood sugar, blood pressure, lipids — is still theoretical in the aggregate, but the individual pieces have reasonable evidence behind them. Better living through chemistry is at least plausible.

Cancer and neurodegenerative disease. Here the toolkit is thin. We don't have great pharmaceutical interventions for preventing either one at the population level. The best argument you can make is that improving metabolic health probably reduces risk for both — and that argument is plausible — but we don't have the data to confirm it.

The Wildcards: Hormones and Peptides

This is the area where I get the most questions and have the least clean answers. When someone says "hormones" or "peptides," they're not talking about one thing — they're talking about dozens of agents, each with its own effect size, its own risk profile, and its own interaction with the person taking it. Saying "hormones extend life" is about as useful as saying "food is healthy." Some of it, in some people, sometimes. We don't have long-term outcome data on most of this. Anyone who tells you otherwise is selling you something.

What Actually Works

I've been pretty cynical up to this point, so let me offer the hope — through simplification.

The holy grail does not exist. There is no single pill, no polypill, no stack that transforms a sedentary, poorly-fed, poorly-rested person into a centenarian. Stop waiting for someone else to solve this for you. Seek a broad perspective and — more importantly — do something about it.

The real move is to build systems and frameworks where you're investing in your own health on a consistent, daily basis. Unglamorous. Boring, even. But it compounds. And unlike rapamycin, empagliflozin, or whatever peptide is being advertised on your feed this week, it's available to you right now, at essentially no cost, and the evidence for it is overwhelming.

You can do this. Stop waiting for someone else to solve it.

3 Bullet Point Summary

• There is no human trial data proving any drug extends lifespan, so we rely on the ITP mouse model — where only rapamycin, 17-alpha estradiol (in males), acarbose, and empagliflozin have actually passed. No nutraceutical has.

• Secondary prevention (treating existing disease) has real mortality benefit; primary prevention (treating healthy people to prevent future disease) has much weaker data, with the strongest exceptions being GLP-1s, SGLT-2s, and aggressive lipid and blood pressure control under the 2026 guidelines.

• Hormones, peptides, and most novel interventions remain unproven for long-term outcomes, and the holy grail longevity pill does not exist.

3 Practical Takeaways

• If you already have a disease, treat it. Secondary prevention is where the evidence is strongest. Hypertension, diabetes, and hyperlipidemia respond well to medication, and ignoring a known problem because you'd rather "solve it naturally" is a losing strategy for most people.

• Stop chasing novelty. Before you buy the peptide, the rapamycin prescription, or the supplement stack, honestly assess your sleep, nutrition, training, and stress. Fundamentals outperform gadgets, and the ITP data backs that up.

• Build a system, not a stack. Consistent daily behavior — sleep, movement, real food, meaningful work, real relationships — is the one intervention with overwhelming evidence and no prescription required. Do something about it today, not after the next lab panel.